The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | The longest reported survival to date in any unselected group of patients with multiple myeloma
In this video, James Berenson, MD, Berenson Cancer Center, West Hollywood, CA, discusses the findings of a recently published retrospective study examining outcomes in an unselected population of newly diagnosed patients with multiple myeloma (MM) treated at his center over almost two decades. Patients included in this study did not undergo frontline autologous stem cell transplantation (autoSCT) and did not receive CAR T-cell therapy or bispecific antibodies. Despite this, an average survival of almost 13 years was reported, the longest to date in any unselected group of patients with myeloma. Dr Berenson emphasizes the importance of considering myeloma as a chronic disease, focusing on patient-specific treatment, and avoiding overly aggressive therapies that may impact quality of life. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
